Ovarian cancer, labeled by the medical society as the deadliest
form of gynecologic cancer, was presented with a rather optimistic prospect in
March this year. Studies on an experimental vaccine and the drug Avastin
(already on the market) have suggested that both may help slow down late-stage
ovarian cancer. The findings were presented at the Society of Gynecologic
Oncology in Chicago in April 2015.
Researchers found that including the vaccine in the standard
treatment of advanced-stage ovarian cancer in women forestalled recurrence. The
FANG vaccine is a type of immunotherapy for ovarian cancer. The other study
showed that administering Avastin after both surgery and chemotherapy stalled
the progression of the cancer, compared with surgery and chemotherapy alone.
As with any experimental
therapy, the long-term effectiveness and safety of these two therapies are yet
to be ascertained. However, the point to note is that the developmental
pipeline for the ovarian cancer
therapeutics market is teeming
with possibilities and this could be the driving force of a currently
restrained market, especially in Asia Pacific.
Even though late-stage drugs for ovarian cancer have displayed
poor efficacy, the positive news is that there have been minimal but steady
improvements during progression-free survival. Investigational drugs such as
trebananib and olaparib have also demonstrated promising results, indicating a
possible approval over the next few years. However, this too is likely to be
marred by low market penetration owing to premium prices and minimal
therapeutic efficacy.
The major challenge that the ovarian cancer therapeutics market
faces is trying to halt the rapid progression of the disease, and that too by
means of personalized and targeted therapy. A new set of drugs being developed
by Constellation Pharmaceuticals and Epizyme is hoping to tackle this exact
challenge.
The American Cancer Society indicates that ovarian cancer is the
fifth most common cause of death by cancer among women, with one in every 75
women at the risk of getting ovarian cancer. Compared to Europe and North
America, Asia has a relatively lower incidence of ovarian cancer. In 2015,
around 21,290 women in the U.S. alone will be diagnosed with ovarian cancer,
close to 14,200 of which will die from the disease this year.
Scientists all over the world continue to study the genes that
are responsible for familial ovarian cancer and increased research activities
in this field are not only expected to yield new drugs for the prevention and
treatment of ovarian cancer but are also estimated to boost the growth of the
ovarian cancer therapeutics market.
A study conducted by MRRSE Research on the ovarian cancer
therapeutics market maps the growth and development of the market in Asia
Pacific. The report forecasts that the market is likely to grow at a slow rate
of 5.1%, reaching a value of US$417.6 million by 2020. The Asia Pacific market
for ovarian cancer therapeutics, according to MRRSE Research, is primarily
driven by inflation and the rising prevalence of ovarian cancer.
Even though targeted therapies for the treatment of ovarian
cancer lag significantly behind other types of cancers, continued interest in
novel molecular targets could help put the ovarian cancer therapeutics market
on track.
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Disease
Pathophysiology
2.1.1 Ovarian Cancer –
A Group of Distinct Diseases
2.1.2 Ovarian Cancer
is Highly Heterogenic with Multiple Mutations and Affected Signaling Pathways
2.2 Symptoms and
Diagnosis
2.3 Risk Factors
2.3.1 Age
2.3.2 Inherited
Genetic Mutations
2.3.3 Greater Number
of Lifetime Ovulations
2.3.4 Weight
2.3.5 Previous Medical
Conditions
2.4 Treatment
Algorithm
2.4.1 Surgery
2.4.2 First-Line
Chemotherapy
2.4.3 Maintenance
Therapy
2.5 Recurrent Disease
3 Marketed Products
3.1 Carboplatin
3.2 Paclitaxel
3.3 Gemcitabine
3.4 Topotecan
3.5 Pegylated
Liposomal Doxorubicin
3.6 Yondelis
3.7 Avastin
4 Product Pipeline
4.1 Overview of
Pipeline by Phase and Route of Administration
4.2 Overview of
Pipeline by Molecule Type, Mechanism of Action and Molecular Target
4.2.1 Molecular
Targets in the Developmental Pipeline
4.3 Clinical Trials
4.3.1 Clinical Trial
Duration
4.3.2 Clinical Trial
Size
4.3.3 Failure Rate
4.3.4 Discussion
4.4 Late-Stage Drugs
in Developmental Pipeline
4.4.1 Niraparib
4.4.2 Olaparib
4.4.3 Vargatef
4.4.4 Trebananib
4.4.5 Farletuzumab
4.4.6 Karenitecin
4.5 Discussion
Send An Enquiry : http://www.mrrse.com/enquiry/112
5 Market Forecasts
5.1 Asia-Pacific
5.1.1 Overview
5.1.2 Treatment Use
Patterns and Revenues in Asia-Pacific Markets
5.2 India
5.2.1 Treatment Use
Patterns
5.2.2 Annual Cost of
Therapy
5.2.3 Market Forecast
5.3 China
5.3.1 Treatment Use
Patterns
5.3.2 Annual Cost of
Therapy
5.3.3 Market Forecast
5.4 Japan
5.4.1 Treatment Use
Patterns
5.4.2 Annual Cost of
Therapy
5.4.3 Market Forecast
5.5 Australia
5.5.1 Treatment Use
Patterns
5.5.2 Annual Cost of
Therapy
5.5.3 Market Forecast
5.6 Drivers and
Barriers
5.6.1 Drivers
5.6.2 Barriers
6 Deals
6.1 Licensing Deals
6.1.1 Clovis Oncology
Enters into Licensing Agreement with Pfizer for PF-01367338
6.1.2 PharmaMar Enters
into Licensing Agreement with Janssen for Yondelis
6.1.3 Hana Enters into
Licensing Agreement with Tekmira
6.1.4 AstraZeneca
Enters into Licensing Agreement with Merck for MK-1775
6.1.5 Tesaro Enters
into Licensing Agreement with Merck Sharp & Dohme for Cancer Drug
6.1.6 Oasmia Enters
into Licensing Agreement with Medison for Paclical
6.1.7 Orion Enters
into Agreement with Oasmia
6.1.8 Ohio University
Enters into Licensing Agreement with Phosplatin
6.1.9 Genta Enters
into Licensing Agreement with Daiichi Sankyo
6.1.10 Celldex Enters
into Licensing Agreement with the Ludwig Institute for Cancer Research
6.1.11 NanoCarrier
Enters into Licensing Agreement with Kowa for NC-6300
6.2 Co-development
Deals
6.2.1 Bristol-Myers
Squibb Enters into Co-development Agreement with Ono Pharma
6.2.2 Merck Enters
into Co-development Agreement with Endocyte for Cancer Drug
6.2.3 Pfizer Enters
into Research Agreement with BC Cancer Agency and Vancouver Prostate Centre
6.2.4 Almac Discovery
Enters into an Agreement with Queen’s University Belfast for Drug Discovery
7 Appendix
7.1 All Pipeline Drugs
by Phase
7.1.1 Discovery
7.1.2 Preclinical
7.1.3 IND/CTA-Filed
7.1.4 Phase I
7.1.5 Phase II
7.1.6 Phase III
7.1.7 Pre-Registration
7.2 Market Forecasts
to 2020
7.2.1 Asia-Pacific
7.2.2 India
7.2.3 China
7.2.4 Japan
7.2.5 Australia
7.3 Abbreviations
7.4 Bibliography
7.5 Research
Methodology
7.5.1 Coverage
7.5.2 Secondary
Research
7.5.3 Primary Research
7.5.4 Therapeutic
Landscape
7.5.5 Geographical
Landscape
7.5.6 Pipeline
Analysis
7.6 Expert Panel
Validation
7.7 Contact Us
7.8 Disclaimer
Upcoming
Report :
· Profenofos Market - Global Industry Expert
Opinions Analysis, Emerging Opportunities,Market Size, Share, Growth Drivers,
Market Trends, Statistics And Forecast 2015 – 2020 http://www.mrrse.com/profenofos-market
Profenofos is an
organophosphorus insecticide which is used to kill pests that damage crop and
thus, affects the overall agricultural productivity. Profenofos chemical name
is 0-4-bromo-2- chlorophenyl Oethyl S-propyl phosphorothioate. The molecular
weight of profenofos is approximately 373. Profenofos is used as an ovicide and
larvicide in order to kill insects and larvae of various insects. Profenofos
intoxication has resulted mainly due to the accumulation of acetylcholine at
the nerve endings. Profenofos is an amber coloured liquid. Profenofos generally
has a garlic-like odour. Profenofos has a boiling point of 110oC. Profenofos is
usually stable at neutral and slightly acidic conditions however; profenofos
turns unstable under alkaline conditions. Profenofos being highly soluble in
organic solvents helps in easy application of insecticides on plants.
Profenofos is highly flammable in nature owing to the chemical properties of
the solvents in which it is dissolved. Profenofos is effective owing to its
ability to inhibit Acetylcholinesterase (AChE) in the pest. Profenofos has to
be stored in well ventilated room. Profenofos as per WHO belongs to class II of
the overall toxicity class. Profenofos widely finds application as insecticide,
acaricide or miticide.
· Polyethylene Terephthalate (PET) Resin
Market - Global Industry Expert Opinions Analysis, Emerging Opportunities,
Market Size, Share, Growth Drivers, Market Trends, Statistics And Forecast 2015
– 2020
Polyethylene terephthalate
(PET) is a thermoplastic polymer that belongs to the family of polyester.
Polyethylene terephthalate resin was introduced for commercial use as textile
fiber and film in 1953. Polyethylene terephthalate (PET) in its natural state
is semi-crystalline colorless resin. Polyethylene terephthalate varies from
semi rigid to rigid mainly on the basis of the method used for processing it.
Polyethylene terephthalate is light weight in nature and has good gas barrier and
alcohol barrier properties. PET becomes white when it is exposed to chloroform
and other chemicals such as toluene. Polyethylene terephthalate is generally
manufactured from terephthalic acid or dimethyl terephthalate and ethylene
glycol. PET offers excellent wear resistance, high flexural modulus, superior
dimensional stability and low coefficient of friction. Polyethylene
terephthalate being highly versatile material is widely used in the
manufacturing of mechanical and electromechanical parts. It is one of the most
widely recycled polymers. Polyethylene terephthalate can be easily
depolymerized to yield the constituent monomers. After the purification
process, the monomers can be further used to manufacture new polyethylene
terephthalate. PET is generally used in the synthetic fibers that are used in
manufacturing of containers used for the packaging of food, beverage and other
liquids.
About Us
Market Research Reports Search Engine (MRRSE) is an
industry-leading database of market intelligence reports. Headquartered in New
York, U.S., MRRSE is driven by a stellar team of research experts and advisors
trained to offer objective advice. Our sophisticated search algorithm returns
results based on the report title, geographical region, publisher, or other keywords.
MRRSE partners exclusively with leading global publishers to
provide clients single-point access to top-of-the-line market research. MRRSE’s
repository is updated every day to keep its clients ahead of the next new trend
in market research, be it competitive intelligence, product or service trends
or strategic consulting.
Contact
Us:
State
Tower,
90
State Street,
Suite
700,
Albany
NY - 12207
United
States
Tel:
+1-518-618-1030
Email:
sales@mrrse.com
Website:
http://www.mrrse.com/
